Early Breast Cancer Content | Docwire News

Early Breast Cancer

Advertisement

Neoadjuvant Immune Checkpoint Inhibitors More than Effective than Adjuvant in Early Breast Cancer

Rob DillardTriple-Negative Breast Cancer | March 25, 2025

New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.

Assessing the Breast Cancer Index in Premenopausal Women With Early-Stage HR+ Breast Cancer

Rob DillardHR Breast Cancer | March 25, 2025

The Breast Cancer Index assists in decision-making regarding adjuvant endocrine therapy for hormone receptor-positive BC.

Dan Forche, CEO of PreludeDx, on Molecular Diagnostics, Precision Medicine for Breast Cancer

Rob DillardBreast Cancer News | March 26, 2025

Dan Forche, CEO of PreludeDx, a leader in precision medicine for early-stage breast cancer, discusses DCISionRT.

Advertisement

Advertisement

Advertisement

Latest News

PENELOPE-B Final Analysis: Palbociclib Shows No Survival Benefit in High-Risk HR+/HER2- Breast Cancer

April 5, 2025

EU Approves Enhertu for HR-Positive, HER2-Low, HER2-Ultralow Metastatic Breast Cancer Following Endocrine Therapy

April 4, 2025

Interim SERENA-6 Data: Camizestrant Significantly Improves PFS in First-Line HR+/HER2- Advanced Breast Cancer With ESR1 Mutations

April 4, 2025